Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Ablynx N.V. maintains 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 7 distinct examiners, indicating a broad spread of individual oversight for the portfolio. The matters are further organized across 4 distinct art units, which suggests the company's intellectual property spans multiple specialized examination groups within the patent office. This diversity in art units and examiners means the company must navigate various internal standards and technical perspectives simultaneously.
The busiest examiner for the portfolio is WANG, CHANG YU, who is currently managing 1 pending office action. Because each of the 7 distinct examiners handles 1 pending office action, the workload is distributed across the 7 individuals. This lack of concentration means that no individual examiner's specific tendencies will dominate the prosecution outcomes for the current 7 pending actions. Practitioners can view this as a decentralized prosecution environment where the 4 distinct art units provide a wide base of technical review. The 1 pending office action assigned to WANG, CHANG YU is part of the total 7 pending office actions, highlighting the examiner variety within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
| No statute on record | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17723543 | SERUM ALBUMIN BINDERS | TAYLOR, LIA ELAN | — |
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17128570 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY | SKELDING, ZACHARY S | 12d |
| 18404145 | SERUM ALBUMIN BINDERS | WANG, CHANG YU | — |
| 18508693 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM | OUSPENSKI, ILIA I | — |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | DAHLE, CHUN WU | — |
| 17723543 | SERUM ALBUMIN BINDERS | TAYLOR, LIA ELAN | — |
| 17540310 | BISPECIFIC NANOBODIES | AEDER, SEAN E | — |
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1642 | 1 |
| 1644 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18404145 | SERUM ALBUMIN BINDERS | WANG, CHANG YU | — | §112 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18508693 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM | OUSPENSKI, ILIA I | — | §112 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | DAHLE, CHUN WU | 1641 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17723543 | SERUM ALBUMIN BINDERS | TAYLOR, LIA ELAN | 1641 | §102§112 | Final Rejection | — | Pending | Apr 19, 2022 |
| 17540310 | BISPECIFIC NANOBODIES | AEDER, SEAN E | 1642 | — | Final Rejection | — | Pending | Dec 02, 2021 |
| 17128570 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY | SKELDING, ZACHARY S | 1644 | Other | Final Rejection | 12d | Pending | Dec 21, 2020 |
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | 1678 | §102§112 | Final Rejection | — | Pending | Dec 14, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial